Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
University of Washington
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01355393CT.gov Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00791037CT.gov Vaccine Therapy in Treating Patients With Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00513695CT.gov Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | — | Completed | — | — | — |
NCT00425672CT.gov ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment | — | Completed | — | — | — |
NCT00343109CT.gov Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer | — | Completed | — | — | — |
NCT00063934CT.gov Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00028496CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | — | Completed | — | — | — |
NCT00003199CT.gov Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Male Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | University of Washington | P2 | BBB · 72 |
| Cyclophosphamide | Wake Forest University Health Sciences | P2 | BBB |
| Irinotecan | University of California, Irvine | P2 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P2 | BBB |
| Cediranib | University of Chicago | P2 | BB |
| Capecitabine | Jonsson Comprehensive Cancer Center | P2 | BB |
| Tamoxifen | Jose Pablo Leone | P3 | BB |
| Sargramostim | University of Washington | P2 | BB |
| Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
+42 more in the Male Breast Carcinoma cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Male Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-male-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →